Who Paid My Doc
Robert Garver
Pulmonary Disease Andalusia, AL Medical Doctor
NPI 1639113707 CMS profile 210065
822 South Three Notch St, Suite B, Andalusia, AL 36420
General payments
$9,700
Research payments
$4,565
Ownership & investment interest
$0
Research they led as principal investigator
$4,557,447
Through program year 2025, Robert Garver of Andalusia, AL is reported in the CMS Open Payments database as having received $9,700 across 103 general payments and $4,565 in research payments paid to them. Separately, studies naming them as principal investigator received $4,557,447 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $2,094 | 10 | |
| 2024 | General | $2,464 | 24 | |
| 2024 | Research | $1,259 | 9 | |
| 2023 | General | $2,775 | 13 | |
| 2021 | General | $153 | 10 | |
| 2020 | General | $739 | 14 | |
| 2019 | General | $3,568 | 42 | |
| 2019 | Research | $1,212 | 13 |
Beside peers
- Robert Garver
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Robert Garver were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Robert Garver | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,568 | $377 | $109–$1,340 | $163 |
| 2020 | $739 | $230 | $56–$907 | $114 |
| 2021 | $153 | $269 | $68–$1,072 | $132 |
| 2022 | $0 | $390 | $100–$1,457 | $149 |
| 2023 | $2,775 | $419 | $114–$1,659 | $160 |
| 2024 | $2,464 | $476 | $123–$1,818 | $164 |
| 2025 | $0 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
135 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Alabama
Related records
Pulmonary Disease in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.